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Abstract Classic galactosemia is a rare inherited disorder of
galactose metabolism caused by deficient activity of galactose-
1-phosphate uridylyltransferase (GALT), the second enzyme of
the Leloir pathway. It presents in the newborn period as a life-
threatening disease, whose clinical picture can be resolved by a
galactose-restricted diet. The dietary treatment proves, however,
insufficient in preventing severe long-term complications, such
as cognitive, social and reproductive impairments. Classic galac-
tosemia represents a heavy burden on patients’ and their families’
lives. After its first description in 1908 and despite intense re-
search in the past century, the exact pathogenic mechanisms
underlying galactosemia are still not fully understood. Recently,
new important insights on molecular and cellular aspects of ga-
lactosemia have been gained, and should open new avenues for
the development of novel therapeutic strategies. Moreover, an
international galactosemia network has been established,
which shall act as a platform for expertise and research in
galactosemia. Herein are reviewed some of the latest de-
velopments in clinical practice and research findings on
classic galactosemia, an enigmatic disorder with many
unanswered questions warranting dedicated research.
Introduction
Classic galactosemia (type I galactosemia, OMIM #230400)
is caused by deficient activity of galactose-1-phosphate
uridylyltransferase (GALT, EC 2.7.7.12), the second enzyme
of the main pathway of galactose metabolism, the Leloir path-
way, and its prevalence is 1:16,000-60,000 live-births (Ashino
et al. 1995; Coss et al. 2013; Fridovich-Keil andWalter 2008).
It is an autosomal recessive disorder caused by mutations in
the GALT gene and over 300 variations have thus far been
described (Calderon et al. 2007). Classic galactosemia pre-
sents in the neonatal period as a potentially lethal disorder that
can lead to chronically debilitating complications (Schweitzer
et al. 1993; Waggoner et al. 1990; Waisbren et al. 2012). The
only currently available therapeutic strategy is a life-long die-
tary galactose restriction, which proves insufficient to prevent
long-term complications (Bosch et al. 2004b, 2009).
The first description of galactosemia dates back to 1908.
Since then, and though a considerable understanding of its
molecular, cellular and clinical aspects has been acquired, its
exact pathophysiology is not yet fully elucidated.
Galactose importance in health
Galactose is vital for the human body, exhibiting a broad range
of functions, as a key energy source in pre-weaning infants
and exerting a crucial structural role, being particularly impor-
tant for early development (Coelho et al. 2015a).
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Galactose is a natural aldohexose that occurs mainly in its
D-configuration. It is available as free and bound galactose in
complex carbohydrates (such as oligosaccharides and poly-
saccharides, glycoproteins, and glycolipids). Along with glu-
cose, galactose forms the disaccharide lactose, present in most
animal milks and a key energy source in infants.
Galactose metabolism
The main dietary source of galactose is lactose present in milk
and dairy products. After its ingestion, lactose is hydrolyzed in
the intestinal lumen by lactase into glucose and galactose.
Galactose is transported across the enterocyte brush border mem-
brane by the sodium/glucose active co-transporter SGLT1, and
through facilitated diffusion by the GLUT2 transporter across the
enterocyte basolateral membrane. Upon entering the blood
stream, it is delivered by the portal blood to the liver, the major
site of galactose metabolism, where it is internalized by the low-
affinity high-capacity GLUT2 (Wood and Trayhurn 2003).
The main pathway of galactose metabolism
When released from lactose breakdown, galactose is in its beta
configuration. Once inside the cells, β-D-galactose is epimerized
into its alpha configuration by galactose mutarotase (GALM, EC
5.1.3.3) (Timson and Reece 2003), so that it can enter the Leloir
pathway (Fig. 1). This pathway converts α-D-galactose into
glucose-1-phosphate (Glc-1-P) by the action of three consecutive
enzymes: galactokinase (GALK1) converts α-D-galactose into
galactose-1-phosphate (Gal-1-P); galactose-1-phosphate
uridylyltransferase (GALT) converts Gal-1-P and uridine
diphosphate-glucose (UDP-Glc) into glucose-1-phosphate (Glc-
1-P) and uridine diphosphate-galactose (UDP-Gal); and UDP-
galactose 4′-epimerase (GALE) is responsible for the intercon-
version of UDP-Gal to UDP-Glc, as well as of UDP-N-
acetylgalactosamine to UDP-N-acetylglucosamine in mammals.
UDP-Glc re-enters the pathway so that further galactose is con-
verted into Glc-1-P and UDP-Gal. The Glc-1-P produced by the
Leloir pathway is converted by phosphoglucomutase into glu-
cose-6-phosphate, to be further metabolized via i) the glycolytic
pathway; ii) the pentose phosphate pathway; or iii) the
gluconeogenic pathway. UDP-Gal, in turn, is the galactose donor
for glycosylation reactions.
Alternative pathways of galactose metabolism
Besides the Leloir pathway, three accessory pathways of galac-
tose metabolism have been described (Fig. 1): i) the reductive
Fig. 1 Galactose metabolism. In the Leloir pathway, galactose is
converted to glucose-1-phosphate (Glc-1-P) by the action of three
consecutive enzymes: galactokinase (GALK1), galactose-1-phosphate
uridylyltransferase (GALT), and UDP-galactose 4′-epimerase (GALE).
Alternatively, galactose can be reduced to galactitol by aldose
reductase, oxidized to galactonate, presumably by galactose
dehydrogenase , o r be conver ted in to UDP-Glc , v ia the
pyrophosphorylase pathway, by the sequential activities of GALK1,
UDP-glucose/galactose pyrophosphorylase (UGP), and GALE. GALE
is also responsible for the interconversion of UDP-N-acetylgalactosamine
to UDP-N-acetylglucosamine (not shown). PPi, pyrophosphate
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pathway, ii) the oxidative pathway, and iii) the pyrophos-
phorylase pathway.
Galactose reduction occurs through the polyol pathway,
consisting of two enzymatic reactions involving the
NADPH-dependent aldose reductase (EC 1.1.1.21) and the
NAD+-dependent sorbitol dehydrogenase (EC 1.1.1.14).
Aldose reductase has a broad specificity for monosaccharides,
and can metabolize glucose and galactose, respectively yield-
ing sorbitol and galactitol. Although both sugars are similarly
processed, sorbitol can be further converted to fructose by
sorbitol dehydrogenase, whereas galactitol will accumulate
in cells and tissues. In the lens, galactitol buildup produces a
hyperosmotic effect, leading to swelling of the cells.
Additionally, galactitol production depletes the cell of
NADPH, decreasing glutathione reductase activity, and con-
sequently free radicals accumulation, yielding oxidative stress
and leading to cell death and cataract formation (Lai et al.
2009; Pintor 2012). Elevated galactitol has also been found
in the brain of galactosemic children, where it causes edema
(Belman et al. 1986; Berry et al. 2001; Quan-Ma et al. 1966).
Galactose can also be oxidized to galactonate, although the
respective pathway is still controversial. It is thought to result
from a NAD+-dependent galactose dehydrogenase (D-
galactose:NAD+ oxidoreductase, EC 1.1.1.48) yielding
galactonolactone, which is spontaneously or enzymatically
converted to galactonate. Galactonate can be directly excreted
in this form or further converted via the pentose phosphate
pathway into β-keto-D-galactonate, which subsequently un-
dergoes decarboxylation, liberating carbon C1 to form
xylulose (Lai and Klapa 2004; Wehrli et al. 1997).
Neither the reductive nor the oxidative pathways in-
volve any of the Leloir enzymes. The pyrophos-
phorylase pathway, however, depends on GALK1 and
GALE, as it involves the GALK1-catalyzed galactose
phosphorylation to Gal-1-P followed by galactose incor-
poration into UDP-Gal catalyzed by UTP-dependent
glucose/galactose pyrophosphorylase (UGP, EC
2.7.7.10). UDP-Gal is then epimerized by GALE into
UDP-Glc, from which a second pyrophosphorylase reac-
tion generates Glc-1-P and UTP. This pathway has been
suggested as a route of endogenous galactose production
(Gitzelmann 1969). The major source of endogenous
galactose is, however, the lysosomal hydrolysis of
galactose-containing glycoproteins, glycolipids and pro-
teoglycans (Berry et al. 1997).
Several studies have provided quantitative evidence for
whole body de novo galactose synthesis in healthy and galac-
tosemic subjects, estimated between 0.48 and 1.71 mg/kg/h in
patients and not influenced by short-term exogenous galactose
(Berry et al. 2004; Ning et al. 2000; Schadewaldt 2004;
Schadewaldt et al. 2014). Notably, it is considerably higher
in infants and children, gradually diminishing until adulthood
(Berry et al. 2004; Schadewaldt 2004).
The molecular biology of classic galactosemia
GALT protein
GALT is a ubiquitous enzyme with a remarkable degree of
conservation throughout evolution. The first insights into
GALT structure came from the X-ray crystallographic
structure of E. coli GalT, revealing this enzyme is a dimer
with two active sites, each formed by amino acids from
both subunits (Wedekind et al. 1995). Only recently the
crystallographic structure of human GALT was reported
(McCorvie et al. 2016) (Fig. 2), confirming the major bac-
terial GalT structural features, while revealing relevant dif-
ferences that support a more accurate interpretation and/or
prediction of the effect of mutations on GALT structure-
function. The human GALT active site contains the H184-
P185-H186 sequence, conserved among all known
uridylyltransferases (Fig. 2), corresponding in E. coli
GalT to residues 164–166 (Field et al. 1989; Wedekind
et al. 1995). The Glc-1-P binding site is formed by K334,
F335, V337, Y339, E340, and Q346 from one chain, along
with Q188 and N173 from the other chain. Uridylylation
appears to induce a conformational change of GALT, with
UMP-GALT presenting a more compact structure than
apo-GALT (McCorvie et al. 2016). The fact that both bac-
terial and human GALT were crystal l ized in the
uridylylated form supports previous proposals of its cata-
lytic mechanism. GALT catalyzes the transfer of an uridyl
group from UDP-Glc to Gal-1-P through a double dis-
placement mechanism involving a transiently uridylylated
histidine residue (Fig. 3) (Thoden et al. 1997; Wong and
Frey 1974a, b). In the first step of this ‘ping-pong’ mech-
anism, an electron pair from a histidine side-chain imidaz-
ole ring in the active site (H186 in human GALT) attacks
the UDP-Glc α-phosphate, resulting in a covalently
uridylylated intermediate (UMP-enzyme) and releasing
Glc-1-P. In the second reaction step, the UMP moiety is
displaced from the enzyme by Gal-1-P, thereby
regenerating the active site and yielding the second prod-
uct, UDP-Gal (Wedekind et al. 1996; Wong and Frey
1974b). GALT is a metalloenzyme, although the role of
bound metals is likely structural. Each bacterial GalT
monomer harbors one zinc ion (bound to C52, C55,
H115, H164) and one iron ion (bound to E182, H281,
H299, H301). Whereas zinc has been proposed to stabilize
the bacterial GalT active site thereby being essential for
activity, iron is thought to play a structural role
(Geeganage and Frey 1999). The zinc binding residues in
E. coli GalT are poorly conserved in human GALT.
However, the structure of human GALT revealed that a
zinc ion is bound to residues E202, H301, H319, H321
(Fig. 2) equivalent to the bacterial GalT iron-binding site.
Indeed, and similarly to the proposed role of iron in
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bacterial GalT, this zinc site was shown to structurally sta-
bilize human GALT and prevent its aggregation (McCorvie
et al. 2016).
GALT gene—clinically relevant variations
The GALT gene is located in the 9p13 region, it is arranged into
11 exons spanning ≈ 4.0 kb of genomic DNA (NG_009029.1),
and is expressed as a housekeeping gene. Analysis of ∼4 kb of
the GALT promoter identified three GC-rich Sp1 sites, an
imperfect non-palindromic AP-1 site (TCAGTCAG at −126 to
−119), a CAAT box, two E-box motifs spaced 23 bp apart (at
−146 to −141 bp – CAGGTG and at −117 to −112 bp –
CACGTG), and no TATA box sequence (Elsas et al. 2001;
Leslie et al. 1992).
An Alu repeat motif with evidence for length variation has
been identified in intron 10 (Flanagan et al. 2004). It consists
of a polyadenine nucleotide repeat with three length variants,
(A)17, (A)24, and (A)29 at frequencies of 47.5, 50.0, and
2.5%, respectively. These length variants have defined
Fig. 3 The catalytic mechanism
of GALT. In the first step of the
reaction, the Nε2 of His186
attacks the α-phosphate of UDP-
Glc, releasing Glc-1-P and
forming the covalent uridylyl-
enzyme intermediate; in the
second step, the intermediate
reacts with Gal-1-P to produce
UDP-Gal
Fig. 2 Crystallographic structure of human GALT. Cartoon
representation of uridylylated human GALT crystallographic structure
obtained in complex with galactose-1-phosphate (PDB code 5IN3).
Each monomer is colored either in cyan or light orange. Active site
residues H184-P185-H186 in red sticks; covalently linked UMP in blue
sticks; galactose 1-phosphate in yellow sticks; residue Q188, responsible
for UMP stabilization and site of the most common mutation (Q188R) in
classic galactosemia in green sticks; zinc (purple sphere) binding ligands
in gray sticks
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associations with particular GALT alleles. The p.Q188R and
p.K285Nmutant alleles are in linkage disequilibriumwith the
(A)17 and (A)24 Alu variants, respectively, while (A)29 is
only found associated with the p.N314D allele (see below)
(Flanagan et al. 2004; Fridovich-Keil and Walter 2008).
At present, there are 336 different variations described
at the GALT locus (available at: http://www.arup.utah.edu/
database/GALT/GALT_display.php, last surveyed January
2017) (Calderon et al. 2007). A few of these otherwise
rare mutations are common, the most frequent being the c.
563A>G transition in exon 6 (CAG→ CGG), leading to a
substitution of a strictly conserved glutamine to an argi-
nine at residue 188 of human GALT (p.Q188R), two res-
idues after the H184-P185-H186 active site. This mutation
accounts for ∼64% of all galactosemic alleles in
Caucasian populations, being the most common among
people of European ancestry. In Europe, p.Q188R shows
a gradient of increasing frequency in the North-Western
direction, reaching its highest frequency in Ireland, where
it accounts for 92–94% of galactosemic alleles. p.Q188R
is the sole variant among the Republic of Ireland Traveller
population, where its incidence is estimated to be 1 in 430
(Coss et al. 2013; Flanagan et al. 2010; Suzuki et al.
2001). The consideration that p.Q188R is the most prev-
alent variation could be biased toward non-Asian origins,
since both Chinese and Indian populations (contributing
to ∼35% of the World’s population) are largely
understudied. p.Q188R was identified in 2.7% of a small
cohort of Indian galactosemic patients (Singh et al. 2012),
whereas it has never been identified in Chinese or
Japanese (or descendant) patients (Ashino et al. 1995;
Hirokawa et al. 1999; Suzuki et al. 2001). This mutation
is described as giving rise to a non-functional variant.
Studies on its bacterial homologue revealed the loss of
one H-bond established with UDP-Gal (Geeganage and
Frey 1998). In human GALT, p.Q188R has been proposed
to cause a destabilization of UMP-GALT (Lai et al. 1999),
which was further demonstrated by McCorvie et al. who
obtained partially uridylylated (∼8%) p.Q188R GALT af-
ter over-night incubation with UDP-Glc (McCorvie et al.
2016). This observation contradicted previous hypotheses
of an over-stabilization of UMP-GALT based on homolo-
gy modeling (Coelho et al. 2014a, b; Facchiano and
Marabotti 2010; Marabotti and Facchiano 2005).
Moreover, McCorvie and co-workers confirmed the in-
creased aggregation propensity of p.Q188R (Coelho
et al. 2014b), proposed therein to result from its lower
uridylylation (McCorvie et al. 2016). As compared to
uridylylated control p.N314D GALT, p.Q188R also pre-
sented a less compact and more elongated shape, similarly
to control apo-GALT, reinforcing that some misfolding
features might be associated with decreased uridylylation
(McCorvie et al. 2016).
Patients homozygous for the p.Q188R variant demonstrate
essentially no residual RBCGALTactivity, and homozygosity
for this allele is often associated with a poor outcome
(Robertson et al. 2000; Shield et al. 2000). Transformed lym-
phoblasts from homozygous p.Q188R patients and heterolo-
gous expression in bacterial and yeast systems revealed that
this variant displays less than 2% of control activity and poor-
ly alleviates galactose toxicity when expressed in a ΔgalT−
E. coli strain (Coelho et al. 2014b, 2015c; Elsas et al. 1995;
Fridovich-Keil and Jinks-Robertson 1993).
The second most common mutation of European origin is
c.855G>T in exon 9 (AAG → AAT), leading to a lysine to
asparagine substitution at residue 285 of human GALT,
p.K285N. This mutation is particularly frequent in countries
of Central and Eastern Europe, accounting for 26–34% of
galactosemic alleles (Greber-Platzer et al. 1997; Kozák et al.
1999; Lukac-Bajalo et al. 2007; Suzuki et al. 2001;
Zekanowski et al. 1999). The Czech, Slovak, Polish, and
Austrian galactosemic populations present the highest
p.K285N frequencies relatively to other European popula-
tions, suggesting a Slavic origin. It has also never been iden-
tified in Asian patients (Ashino et al. 1995; Hirokawa et al.
1999; Suzuki et al. 2001). Heterologous expression of this
variant revealed essentially null activity (Coelho et al.
2014b; Riehman et al. 2001), and homozygosity in patients
is associated with essentially null RBC GALT activity and
with a severe clinical phenotype (Zekanowski et al. 1999).
In exon 5, the C→T transition at nucleotide c.404 (TCpG
→ TTG) leads to a serine to leucine substitution at residue 135
of human GALT, p.S135L. This variant is found almost en-
tirely in individuals of African origin, accounting for approx-
imately 48% of African American and 91% of South African
GALT mutant alleles (Lai et al. 1996; Manga et al. 1999).
Heterologous expression in bacteria or yeast revealed, respec-
tively, less than 0.1 and 2.7% of control activity (Coelho et al.
2014b; Riehman et al. 2001). Notably, p.S135L appears to
exhibit tissue specificity: homozygous patients have essential-
ly no GALT activity in RBC, presenting ∼5.5% of control
activity in leukocytes, while liver and intestinal mucosa biop-
sy specimens display ∼10% of normal GALT activity (Lai
et al. 1996). Additionally, homozygous patients are capable
of converting galactose to CO2 at a rate comparable to control
subjects and homozygosity for this mutation is often associat-
ed with milder clinical outcomes (Berry et al. 1997; Lai and
Elsas 2001; Lai et al. 1996; Robertson et al. 2000).
Duarte and Los Angeles variants
The first known variant of GALT protein is the Duarte variant,
named after the city where it was described. The Duarte allele
—Duarte-2, D2 or simplyD— is biochemically defined as an
isoformwith a characteristic isoelectric focusing pattern, and a
RBC enzyme activity approximately 50% of the control.
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Heterozygotes for the Duarte allele present 75% of GALT
activity, homozygotes present 50% activity, and compound
heterozygotes for the Duarte allele and a classic galactosemia
allele present 25% activity in RBC (Elsas et al. 1994).
Later, another variant presenting the same electrophoretic
mobility profile as D2 but mildly elevated activity was iden-
tified and named as the Los Angeles variant (Duarte-1, D1 or
LA) (Langley et al. 1997; Ng et al. 1973). Both variants are
now known to be associated with the AAC→GAC transition
at nucleotide c.940 in exon 10, leading to an asparagine to
aspartate substitution at residue 314 of human GALT
(p.N314D). The charge change caused by the substitution of
a basic to an acid residue is proposed to be responsible for the
resulting specific electrophoretic pattern (Reichardt 1991).
The different activities displayed by each variant result from
additional base changes: the Los Angeles allele carries
p.N314D in linkage disequilibrium exclusively with the
synonymous mutation c.652C>T (p.L218L), whereas the
Duarte allele carries p.N314D in linkage disequilibrium with
c . 3 78 - 2 7G>C ( IVS4 - 27G>C ) , c . 5 07 + 62G>A
(IVS5 + 62G>A), c.508-24G>A (IVS5-24G>A) and a 4-bp
deletion in the GALT promoter, 116–119 bases upstream the
first methionine codon (c.-119_-116delGTCA) (Kozak and
Francova 1999; Podskarbi et al. 1996). This deletion removes
the first two nucleotides of the −117 to −112 bp E-box motif
(CA, located at −117 and −116 bp), which however does not
change the E-box motif of CACGTG from −117 to −112 bp,
since there are three repeats of GTCA in sequence, and the
middle GTCA tetrad fills the deleted CA of the E-box motif
(Fig. 4). There is, however, a reduction in the spacing between
the two E-box motifs that likely alters trans–acting factors
binding, thus impairing positive regulation of GALT expres-
sion. Furthermore, this deletion affects the AP-1 site from
−124 to −117 bp (TCAGTCAG), as it removes the terminal
guanine of thismotif, which can also reduceGALTexpression.
Functional analyses carried out by two independent groups
demonstrated that this deletion in the GALT promoter is in-
deed the major factor contributing to the diminished expres-
sion and activity of the Duarte variant (Elsas et al. 2001;
Trbušek et al. 2001).
At present, p.N314D is a common allele with a frequency
of approximately 11% in European populations and lower
frequencies in other populations, with an 8.3% pan-ethnic
frequency (Carney et al. 2009; Suzuki et al. 2001).
Interestingly, a study on the origin and distribution of the
Duarte allele suggested that p.D314 is in fact the ancestral
allele and that p.N314 only arose early in human evolution
once humans migrated out of Africa (Carney et al. 2009).
Functional and structural characterization of the p.N314D
variant confirmed that, in vitro, it displays enzymatic activity
essentially identical to control, although with impaired con-
formational stability (Coelho et al. 2014b). This variant was
recently used for the first description of the crystallographic
structure of human GALT (McCorvie et al. 2016).
Biochemical features and follow-up
Severe impairment of GALT activity results in the accumula-
tion of metabolites such as galactose, Gal-1-P, galactitol, and
galactonate, and in deficiency of UDP-Gal and UDP-Glc.
Galactose only differs from glucose in the hydroxyl moiety
configuration at the carbon-4 position. However, galactose is less
stable and more susceptible to the formation of nonspecific
glycoconjugates (Decombaz et al. 2011). The human body is
able to metabolize large galactose amounts, as evidenced by its
rapid clearance from blood: 50% of radiolabeled galactose is
found in glucose pools within 30 min after intravenous adminis-
tration. For nursing infants, galactose conversion to glucose is
crucial to maintain euglycemia, since 40% of calories derive
from lactose hydrolysis into galactose and glucose (Coelho
et al. 2015a). In contrast to healthy infants, galactosemic new-
borns accumulate galactose in the blood, as well as in other cells
and tissues, and they present high urinary galactose concentra-
tions, whereas blood glucose levels can fall to hypoglycemic
levels. Upon initiation of dietary galactose restriction—the cur-
rent standard of care—blood galactose levels fall quickly, but
always remain elevated. Additionally, patients also present high
RBC Gal-1-P concentrations which, despite falling dramatically
upon diet implementation, never normalize (Gitzelmann 1995).
Gal-1-P accumulation has been widely pointed out as a key
pathogenic agent (Gitzelmann 1995; Lai et al. 2009; Leslie
2003; Tang et al. 2010). Gal-1-P has been described to inhibit
in vitro enzymes involved in carbohydrate metabolism, such as
UDP-glucose pyrophosphorylase, glucose-6-phosphatase,
glucose-6-phosphate dehydrogenase, phosphoglucomutase, and
Fig. 4 The GALT promoter deletion of the Duarte allele. The GALT
promoter presents an AP-1 site from −126 to −119 bp (TCAGTCAG)
and two E-box motifs from −146 to −141 bp (CAGGTG) and from −117
to −112 bp (CACGTG). The −119 to −116 GTCA deletion removes the
first two nucleotides (CA, in bold) of the −117 to −112 bp E-box motif.
The middle tetrad GTCA fills the deleted CA of the E-box motif;
however, the spacing between the two E-box motifs is reduced, and the
terminal G of the AP-1 site is removed. Nucleotide +1 is the A of the
ATG-translation initiation codon
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glycogen phosphorylase (Gitzelmann 1995). Additionally, Gal-
1-P has been described to inhibit inositol monophosphatase,
which could lead to a reduced inositol pool. Brain autopsy of
two newborn patients showed a reduction of up to 80% free
inositol (Ins) and phosphatidyl-inositol (PtdIns) comparatively
with healthy controls, and rats with a high-galactose diet exhib-
ited a reduction of up to 30% of free Ins and PtdIns (Bhat 2003).
There is also evidence that high levels of Gal-1-P inhibit
galactosyltrans-ferases, which may disturb glycosylation
(Charlwood et al. 1998; Jaeken et al. 1992). Additionally,
UDP-Gal and UDP-Glc levels have been found decreased in a
number of studies (Coss et al. 2012, 2014; Lai et al. 2003a; Ng
et al. 1989). These UDP-hexoses are the galactose and glucose
donors in glycosylation reactions, and several studies have in-
deed reported glycosylation abnormalities in classic galactosemia
(Charlwood et al. 1998; Coman et al. 2010; Coss et al. 2012,
2014; Lebea and Pretorius 2005; Liu et al. 2012; Maratha et al.
2016; Petry 1991; Sturiale et al. 2005).
High galactitol levels have been found in blood, tissues,
and urine of galactosemic patients (Berry et al. 2001; Jakobs
et al. 1995; Palmieri et al. 1999). When dietary treatment is
implemented, most galactitol is cleared via urine, but does not
entirely disappear, likely because of endogenous galactose
production.
Galactonate has been detected in urine and in several tis-
sues of galactosemic patients. However, galactonate in pa-
tients’ plasma is below the detection level, and is not elevated
in the RBC of all galactosemic patients (Ning and Segal 2000;
Wehrli et al. 1997; Yager et al. 2003).
Diagnosis
Acute clinical presentation and diagnosis
Infants with classic galactosemia generally appear asymptom-
atic at birth. However, after a few days of galactose ingestion
through breast and/or formula feeding, children start develop-
ing life-threatening symptoms that, if undiagnosed and un-
treated, may lead to death. Initial symptoms include poor feed-
ing with poor weight gain, vomiting and diarrhea, hepatocel-
lular damage, lethargy, and hypotonia. Progression of this
acute neonatal toxicity syndrome may include the develop-
ment of Gram negative sepsis, cataracts, and pseudotumor
cerebri causing a bulging fontanel (Berry and Walter 2012).
There are several tests to diagnose classic galactosemia.
Screening for reducing substances in urine can be informative;
however, it is not sensitive or specific, leading to false posi-
tives due to fructosuria, lactosuria (from intestinal lactase de-
ficiency), or to conditions that impair blood galactose clear-
ance, such as severe liver disease or antibiotic treatment. In
contrast, if the child is on intravenous feeding, galactosuria
may no longer be present, thus leading to false negatives
(Berry and Walter 2012; Bosch 2006).
A more specific approach is the measurement of galactose
metabolites, such as galactose, Gal-1-P and/or galactitol, in
blood and/or urine. Galactosemic patients present invariably
high RBC Gal-1-P levels. However, benign variants can also
originate increased Gal-1-P levels and diagnosis should not be
done based exclusively on it (Berry 2012; Berry and Walter
2012). Hemolysate Gal-1-P can be measured by different
methods: spectrophotometric coupled enzymatic assay,
isotope-dilution gas chromatography–mass spectrometry
(GC/MS), or tandem MS (MS/MS) (Chen et al. 2002a;
Jensen et al. 2001; Schadewaldt et al. 2003). Another ap-
proach is the Paigen test, which quantifies total galactose
through a microbiological assay which is, however, not suit-
able for automation and is sensitive to antibiotic therapy taken
by newborns or their mothers (Beutler 1991). Nursing infants
with galactosemia also present high galactitol amounts in their
urine and plasma, which stay higher than in controls, even
upon diet implementation. Galactitol in urine can be measured
by nuclear magnetic resonance (NMR) or GC/MS, whereas in
RBC GC/MS is required due to its higher sensitivity (Chen
et al. 2002b; Palmieri et al. 1999; Wehrli et al. 1997; Yager
et al. 2003, 2006).
The gold standard for diagnosis is the GALT activity mea-
surement in RBC, which can be done by the semi-quantitative
Beutler fluorescent spot test or by a preferable quantitative
assay. It can be done indirectly by a coupled enzymatic assay,
or directly by quantifying radioactively labeled Gal-1-P con-
version to UDP-Gal or, alternatively, by quantifying unlabeled
substrates and products by HPLC (Cuthbert et al. 2008;
Lindhout et al. 2010). Classic galactosemic patients usually
present undetectable or less than 1% of control GALT activity
(Elsas 2010). RBC GALT activity analysis is, however, not
suitable for children that have been subjected to blood trans-
fusion within the last 3 to 4 months, since a false-negative
might result.
GALT mutational analysis is currently available in many lab-
oratories for the most common variations, and has been used in
some newborn screening programs to refine the screening pro-
cess. A negative result does not exclude the disease, and full gene
sequencing, including deep intronic regions, may be required
(Coelho et al. 2015b; Wadelius et al. 1993).
Newborn screening
Neonatal screening for classic galactosemia has been debated
for years, but no consensus has been reached. The principles
originally articulated byWilson and Jungner for screening and
later expanded by Pollitt et al. have been accepted as the
criteria for neonatal screening (Clarke 2005; Pollitt et al.
1997). Galactosemia has been excluded from some newborn
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screening programs based on two major arguments: it can be
diagnosed clinically and long-term complications still develop
despite early treatment. Despite Pollitt et al. recognizing that
effective treatment availability was not an absolute prerequi-
site for a disease to be included in newborn screening pro-
grams, galactosemia-specific screening was still not recom-
mended. Nevertheless, there were recommendations for all
samples with increased phenylalanine to be screened for ga-
lactosemia as a secondary test. A later study compared 139
children with metabolic diseases identified by neonatal
screening (17 galactosemic) to 124 children identified on the
basis of clinical symptoms (9 galactosemic), and concluded
that, despite the similar rate of hospitalization, 47% of the
clinically identified children had mental retardation compared
to only 14% of those identified by newborn screening, and
that parental stress tended to be greater in families of children
identified clinically (Waisbren et al. 2002).
Newborn screening for galactosemia is included in several
European countries—Austria, Germany, Hungary, Ireland,
Sweden, Switzerland, The Netherlands—while others—
Turkey, Italy, and Belgium—present pilot programs (EGS
2003; Karadag et al. 2013; Ohlsson et al. 2012). Ireland pre-
sents a high classic galactosemia incidence (1:16,476), espe-
cially in the Traveller population (1:430), and newborn
screening for classic galactosemia has been performed since
1972 (Coss et al. 2013). Irish newborns undergo screening
within 72 to 120 h after birth, while all high-risk Traveller
neonates are evaluated at day 1 or 2. On the other hand,
Sweden presents a relatively low frequency (1:100,000) and
yet newborn screening program includes galactosemia
(Ohlsson et al. 2012). Other countries, such as France and
Portugal do not offer neonatal screening and some, like
Norway, Denmark, and Scotland, have stopped their programs
(EGS 2003; Hansen and Lie 1988; Lund et al. 2012; Shah
et al. 2001). In the USA, screening for galactosemia is cur-
rently offered in all states, and in Canada only two out of ten
provinces offer universal screening (Fridovich-Keil and
Walter 2008; Shah et al. 2001).
Standard of care
Lifelong dietary restriction of galactose has been the therapeu-
tic basis for classic galactosemia since Mason and Turner de-
scribed in 1935 how removing galactose from the diet elimi-
nated the acute clinical presentation.
After the initial symptoms and upon the first suspicion of
galactosemia, patients should be put immediately on a
galactose-restricted diet (Berry and Walter 2012). Commercial
infant formulas appropriate for use in galactosemia management
include elemental and soy formulas. Despite elemental formulas
containing no galactose, there is insufficient evidence that sup-
ports their added value comparatively with soy formulas. In fact,
the latter are most often recommended, except for premature
infants, in which case an elemental formula is preferable (Van
Calcar et al. 2014a).
With the introduction of solid foods, some galactose is
inevitably introduced into the diet. While there is consensus
regarding the restriction of most dairy products, cheese con-
sumption has always been a matter of debate. Some studies
have been developed to elucidate the galactose content in
several cheeses, revealing that most mature cheeses are ade-
quate for galactosemia diet (Portnoi and MacDonald 2009;
Portnoi and MacDonald 2011; Portnoi and MacDonald
2016; Van Calcar et al. 2014b). Galactose is also naturally
found in cereals, offal meats, pulses, fruits, and vegetables;
their galactose content, however, is considerably lower than
in lactose-rich foods (Gropper et al. 2000; Gross et al. 1995;
Gross and Acosta 1991; Kim et al. 2007; Van Calcar et al.
2014b). In addition, galactose can also be found in its complex
form, which is presumably hydrolyzed in the gastrointestinal
tract, rendering galactose available for absorption. However,
presently it is considered that most galactose is actually not
available for digestion (Van Calcar et al. 2014a).
Concerning galactosemia outcome, the significance of
non-dairy foods to the total galactose intake has long been
questioned. Berry et al. demonstrated that a lactose-free diet
highly enriched in fruits and vegetables resulted in a mean
galactose intake of 54 mg per day, and further demonstrated
that the daily ingestion of 200 mg of fruit-derived galactose
(50 mg of pure galactose in fruit juice 4 times per day) during
3 weeks had no impact on RBC Gal-1-P values and relatively
little effect on urinary galactitol levels, despite the patients
having null RBCGALTactivity (Berry et al. 1993). In another
study, Bosch et al. demonstrated that galactose supplementa-
tion for 6 weeks up to a maximum of 600 mg per day—cor-
responding to the amount of galactose in 7 kg of apples, 2.5 kg
of tomatoes or 12 kg of peas—did not result in any physical,
ophthalmological, or biochemical abnormalities (Bosch et al.
2004a). These data suggest that reducing the daily dietary
galactose intake by restricting fruit and vegetables is negligi-
ble and, in the short-term, does not seem to have a significant
impact on the clinical outcome. In a retrospective study,
Hughes et al. reported no difference in long-term complica-
tions of siblings from 14 families (total of 30 subjects) with
lower (<20mg/day) and higher galactose intake (>20mg/day)
(Hughes et al. 2009). Another study reported that the ingestion
of galactose, gradually increased from 300 to 4000mg/day for
a period of 16 weeks, improved the abnormalities in plasma
IgG N-glycan profiles (Coss et al. 2012). Furthermore, the
realization that galactosemic patients endogenously synthe-
size galactose to an extent that far exceeds that from non-
dairy foods has minimized this concern. Accordingly, some
countries have liberalized the therapy, currently advising a
lactose-free diet (Bosch et al. 2004a; Van Calcar et al.
2014a). The international clinical guideline for the
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management of classic galactosemia recommends a life-long
galactose-restricted diet that only eliminates sources of lactose
and galactose from dairy products, allowing mature cheeses,
caseinates, and non-milk foods (Welling et al. 2016).
Pathophysiology and long-term outcome
While the success of early treatment on the acute neonatal
symptoms is unquestioned, the long-term outcome can be
extremely disappointing since many patients develop burden-
some complications.
Cognitive impairment
One of the most frequent and well-established long-term com-
plications is cognitive impairment. Across most studies, IQ
standard scores have been found to be in the low average
(85–100) to borderline-low (<85) range, with considerable
inter-individual variability (Antshel et al. 2004; Doyle et al.
2010; Kaufman et al. 1995; Potter et al. 2008; Waggoner et al.
1990; Waisbren et al. 1983). Motor disturbances, such as co-
ordination, gait, balance, fine motor tremors, and severe ataxia
are quite frequent, as well as memory, speech, and language
problems (Antshel et al. 2004; Hughes et al. 2009; Kaufman
et al. 1995; Potter 2011; Potter et al. 2008, 2013; Robertson
et al. 2000; Schweitzer et al. 1993; Timmers et al. 2011, 2012;
Waggoner et al. 1990; Waisbren et al. 1983, 2012). Speech
and language impairment has been estimated to affect 38–
88% of patients and cannot be solely explained by lower cog-
nitive abilities in general (Hughes et al. 2009; Potter et al.
2008; Robertson et al. 2000; Schweitzer et al. 1993;
Timmers et al. 2011, 2012; Waggoner et al. 1990; Waisbren
et al. 1983). Expressive language is mainly affected, with
receptive language or comprehension being relatively pre-
served (Potter et al. 2008; Timmers et al. 2011). Patients ex-
hibit speech motor abnormalities such as childhood dyspraxia
of speech and voice dysfunction (Potter 2011; Potter et al.
2013), besides impaired cognitive planning of language at
several stages, from conceptualization to lexical and syntactic
planning (Timmers et al. 2012), showing altered neural activ-
ity and connectivity patterns (Timmers et al. 2015a).
Studies on galactosemic patients’ brains have reported
structural abnormalities, such as cerebral and cerebellar atro-
phy, and white matter abnormalities possibly due to altered
myelination (Crome 1962; Haberland et al. 1971; Hughes
et al. 2009; Koch et al. 1992; Krabbi et al. 2011; Lo et al.
1984; Nelson et al. 1992; Wang et al. 2001). A recent study
on the white matter microstructure in galactosemic patients
revealed increased neurite dispersion (i.e., less organized
axons) and lower neurite density (Timmers et al. 2015b).
Impaired galactosylation of glycoconjugates in the brain has
been suggested as the underlying pathogenic mechanism
(Coss et al. 2012; Petry 1991).
Visual and perceptual impairments also occur in galacto-
semic patients and seem to be independent of the IQ (Antshel
et al. 2004; Kaufman et al. 1995; Schweitzer et al. 1993).
Handwriting, reading, and difficulties in mathematics are also
common, and galactosemic children are often academically
retained (Antshel et al. 2004; Schweitzer et al. 1993). School
achievements are below the grades reached by healthy sib-
lings and/or parents. Whereas a comprehensive multidisci-
plinary study on galactosemic adults reported an average
schooling of 1 to 2 years of college, with an occupational level
of skilled manual laborer (Waisbren et al. 2012), another re-
vealed that many patients lacked educational qualifications
and were unemployed (Bhat et al. 2005). Patients are often
described as shy and reserved but generally do not present
behavioral dysregulation (Antshel et al. 2004), and are single
and live with their parents, as only a minority is able to build
up strong partnerships outside the family core (Waisbren et al.
2012). Approximately 40% of patients recognize that galacto-
semia impairs their relationships with other people (Hoffmann
et al. 2012). Bosch and colleagues reported that galactosemia
is seen as a burden by a significant number of patients (39%),
with many feeling different because of the disease (34%), and
believing they are not well understood (22%). Furthermore,
many parents feel the disorder influenced their contact with
the child (73%) and that taking care of a galactosemic child
represents a burden (60%), despite raising their child the same
way as their healthy children (69 and 77%, respectively)
(Bosch et al. 2004b). This study concluded that galactosemia
negatively influences the health-related quality of life
(HRQoL) on the communication, social and, most strikingly,
cognitive domains. In another study, Bosch et al. compared
the course of life of galactosemic patients with that of the
general population and with phenylketonuric patients (Bosch
et al. 2009). Galactosemic patients achieved fewer social and
psychosexual developmental milestones as compared to
healthy or phenylketonuric controls, suggesting that these dif-
ferences result from specific complications of classic galacto-
semia and not from the burden of a chronic disease or lifelong
dietary restrictions. The social and psychosexual development
milestones of men studied in a small cohort appeared severely
delayed, leading to the suggestion that early intervention (e.g.,
social skills training) might improve the patients’ psychoso-
cial competences (Gubbels et al. 2011).
Bone health
Because of their galactose-restricted diet, patients are at risk
for nutritional deficiencies, particularly regarding calcium,
since dairy products are considered its best source for their
high calcium content in casein-micelles (Lewis 2011).
Decreased height and growth rate have been reported.
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However, growth often continues through the late teens, so
that the target height can be reached by children who grow
beyond the age of 18 (Panis et al. 2007;Waggoner et al. 1990).
Treated galactosemic patients are at risk for diminished bone
mineral density (BMD) (Batey et al. 2013; Kaufman et al.
1993; Panis et al. 2004; Rubio-Gozalbo 2002; van Erven
et al. 2017). A patient group with no evidence of nutritional
deficiencies exhibited decreased levels of bone formation and
resorption markers (Panis et al. 2004). Since carboxylated
osteocalcin is a marker for the vitamin K nutritional status,
Panis et al. developed a 2-year randomized clinical trial to
investigate whether vitamin K, given in combination with
calcium and vitamin D, could play a role in the pathophysiol-
ogy of this complication. In fact, they found a statistically
significant increase in osteocalcin carboxylation in both pre-
pubertal and pubertal children receiving supplementation
(Panis et al. 2006).
Batey et al. reported that out of 32 evaluated adult
patients, only 10% were followed by a nutritionist, sug-
gesting nutritional counseling as a strategy to optimize
bone accrual during adolescence and to maintain bone
mass during adulthood (Batey et al. 2013). Nevertheless,
several studies have excluded major nutritional deficien-
cies, and concluded that other intrinsic factors must be
involved (Batey et al. 2013; Kaufman et al. 1993; Panis
et al. 2005, 2006).
Gonadal impairment
The most common complication reported for girls and women
with classic galactosemia is primary ovarian insufficiency
(POI), with an incidence above 80% (Berry 2008;
Fridovich-Keil et al. 2011; Kaufman et al. 1981; Rubio-
Gozalbo et al. 2010;Waggoner et al. 1990). POI clinical mani-
festations range from absent or delayed pubertal development,
primary amenorrhea, secondary amenorrhea or oligomenor-
rhea, and premature menopause. Many female patients do
not spontaneously reach puberty, which has to be induced to
reach a normal pubertal development and prevent sequelae
(Gubbels et al. 2008; Spencer et al. 2013). The proposed patho-
genic mechanisms include ovarian damage due to elevated Gal-
1-P and galactitol; UDP-Gal deficiency causing aberrant glyco-
sylation of glycoconjugates involved in ovarian function; in-
creased apoptosis of maturing follicles, with accelerated follicle
atresia; and possible abnormalities of the immune system, such
as unrecognized auto-ovarian antibodies (Forges et al. 2006; Lai
et al. 2003b; Liu et al. 2000; Rubio-Gozalbo et al. 2010). Two
neonates have been reported to have morphologically normal
ovaries and abundant oocytes (Levy 1996; Levy et al. 1984),
whereas young adult females’ ovaries have been reported to have
a severely decreased number of normal primordial follicles
(Rubio-Gozalbo et al. 2010). Follicle-stimulating hormone
(FSH)—an indirect marker of ovarian reserve—has been found
elevated in patients very early in life up to the onset of puberty
(4 months to 12 years) (Berry 2008; Fridovich-Keil et al. 2011;
Rubio-Gozalbo et al. 2010; Sanders et al. 2009). Anti-Mullerian
hormone (AMH)—a direct marker for ovarian reserve that is
produced by granulosa cells in the developing ovarian folli-
cle—has been found low in female patients (Sanders et al.
2009; Spencer et al. 2013). However, low AMH levels in galac-
tosemia patients might be not only due to follicle depletion, but
might also reflect an impaired follicle maturation (Rubio-
Gozalbo et al. 2010). Indeed, extremely low AMH levels do
not preclude spontaneous pregnancy (Gubbels et al. 2009). In
fact, spontaneous pregnancies occur (Briones et al. 2001; De
Jongh et al. 1999; Gubbels et al. 2009; Kimonis 2001; Ohlsson
et al. 2007; Roe et al. 1971; Samuels et al. 1976; Tedesco et al.
1972). And, whereas in the past women were told to be infertile,
presently women are informed that spontaneous pregnancies
may occur. The term subfertility is more accurate than infertility.
Nevertheless, subfertility remains a major concern for patients
and parents, and physicians are often asked about fertility pres-
ervation options (Spencer et al. 2013; van Erven et al. 2013).
Few studies have examined the male reproductive sys-
tem and, until recently, male fertility was believed not to
be impaired (Gubbels et al. 2013; Rubio-Gozalbo et al.
2010). A study on cryptorchidism in galactosemic indi-
viduals revealed a 25% prevalence (three of the 12
males), compared with ≤1% in the healthy age-matched
population (Rubio-Gozalbo et al. 2006). A more recent
investigation on the reproductive system of 26 galacto-
semic patients demonstrated an increased prevalence of
cryptorchidism (11.6%), with low semen volume, and
lower testosterone, inhibin B and sperm concentrations
than in control subjects—although within the normal
range on average—which might indicate mild defects in
Sertoli and Leydig cell functions (Gubbels et al. 2013).
With the exception of cryptorchidism, these abnormalities
are expected to have little impact on fertility (Gubbels
et al. 2013; Rubio-Gozalbo et al. 2006). Besides the three
fathered pregnancies in the literature, there are no data on
paternity in galactosemic patients other than anecdotal
cases which may be related to a publication bias and to
difficulty in documenting paternity, or to the known social
interaction problems and delayed psychosocial develop-
ment documented in these men (Gubbels et al. 2013;
Waisbren et al. 2012).
Models of classic galactosemia:
toward the understanding of the underlying
pathophysiology
Different cellular and animal models have been developed to
understand the pathogenic mechanisms of classic galactosemia.
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Yeast model
Saccharomyces cerevisiae deleted in theGAL7 gene (the yeast
orthologue of human GALT) shows a growth arrest upon ga-
lactose addition to the medium despite the presence of other
carbon sources (Douglas and Hawthorne 1964, 1966). Using
GALT-deficient yeast, Fridovich-Keil’s group has studied sev-
eral human GALT mutations (Crews et al. 2000; Fridovich-
Keil and Jinks-Robertson 1993; Fridovich-Keil et al. 1995;
Mumma et al. 2008; Ross et al. 2004; Wells and Fridovich-
Keil 1997). Furthermore, the yeast model has been used to
provide new insights on the metabolic role of each of the
Leloir pathway enzymes and galactose metabolites
(Riehman et al. 2001; Ross et al. 2004). Interestingly, GAL1-
(orthologue for the human GALK1 gene) deficient yeast does
not cease to grow upon galactose addition to the growth me-
dium (Ross et al. 2004; Slepak et al. 2005). Additionally, the
yeast model of classic galactosemia has been used to study
gene expression upon galactose exposure (De-Souza et al.
2014; Slepak et al. 2005), revealing that galactose induces
metabolic and endoplasmic reticulum (ER) stress and triggers
the unfolded protein response (UPR).
Bacterial model
Bacterial expression systems have been used to study several
human GALT mutations, by expressing recombinant human
GALT variants (Coelho et al. 2014b; Lai and Elsas 2001; Lai
et al. 1999). Most recombinant human GALT variants displayed
a severely impaired catalytic activity and/or decreased stability,
establishing GALT misfolding and/or aggregation as the patho-
genic mechanism underlying several variants, leading to the clas-
sification of classic galactosemia as a conformational disorder
(Coelho et al. 2014b; McCorvie et al. 2013).
A prokaryotic model with a deletion of the endogenous galT
gene has been employed to evaluate the functional impact of
several human GALT mutations in a cellular context.
Expression of the p.Q188R, p.K285N, p.G175D, and p.P185S
variants failed to alleviate galactose toxicity (Coelho et al. 2015c).
Mouse model
Two decades ago, the first animal model of classic galacto-
semia—aGalt-knockout mouse—was developed (Leslie et al.
1996), displaying a complete loss of Galt activity and accu-
mulating Gal-1-P at levels comparable to those in galacto-
semic humans. However, the mouse was described to remain
healthy despite dietary exposure to galactose. More recently,
another Galt-deficient mouse model was developed by Lai’s
group, using a Galt gene-trapping approach, which exhibited
null Galt activity and Gal-1-P accumulation in RBC (Tang
et al. 2014). Despite some resistance to galactose toxicity,
expanded characterization of the model revealed subtle
phenotypic differences to wild-type mice. Histological exam-
ination of galactose-fed pups revealed hepatic and brain (ce-
rebral and cerebellar) alterations. Additionally, excess galac-
tose also led to manifestation of oxidative stress in mutant
pups (lower GSH/GSSG ratio) comparatively to wild-type or
non-challenged mutant pups. In the long-term, some degree of
growth and fertility impairments also became evident. The
newborn intoxicated pups that survived the galactose insult
manifested a decreased growth rate and weight, even when
normal chow resumed after the weaning period ended, that
was only recovered with puberty. Additionally, mutant mice
exhibited a smaller litter size and a longer time to achieve
pregnancy, suggestive of subfertility.
Fruit fly model
A Galt-deficient Drosophila melanogaster model has also
been developed, which showed a null GALT activity and
Gal-1-P accumulation (Kushner et al. 2010). If exposed to
galactose, these flies succumbed during development; howev-
er, they lived when maintained on a galactose-restricted diet.
In the long-term, Galt-deficient adult flies under a galactose-
restricted diet demonstrated an impaired negative geotaxic
response, suggesting the development of movement impair-
ments. Both galactose lethality and motor impairments could
be rescued by the expression of a wild-type human GALT
transgene (accounting for ≈ 4% of wild-type GALT activity).
A more recent study has shown that GALT deficiency results
in structural synaptic overelaboration and glycosylation ab-
normalities of the flies neuromuscular junction (NMJ), name-
ly reductions in the galactosyl, N-acetylgalactosamine, and
fucosylated moieties (Jumbo-Lucioni et al. 2014a). Mutant
flies on restricted-galactose and high-galactose diets showed
identical movement impairments and overelaborated NMJ ar-
chitecture, reinforcing the notion that classic galactosemia’s
long-term phenotype is independent of dietary galactose.
Additionally, the Wnt trans-synaptic co-receptor and ligand
abundance were shown to be altered. Since signaling of the
Wnt proteinWingless (Wg) is regulated by the heparan sulfate
proteoglycan (HSPG) co-receptor Dally-like protein (Dlp) and
known to drive the NMJ synaptogenesis, the authors hypoth-
esized that UDP-sugar deficiency triggered changes in the
NMJ synaptomatrix glycosylation, including levels of HSPG
Dlp, which subsequently affected the Wnt signaling, causing
an excessive growth and overelaborated architectural com-
plexity. Mutations in the GALK1- or UDP-glucose dehydro-
genase-encoding genes were identified, respectively, as criti-
cal environmental and genetic modifiers of behavioral and
cellular defects. Double GALT and GALK mutants or overex-
pression of UDP-Glc dehydrogenase corrected the glycosyla-
tion defects, the NMJ architectural alterations and the move-
ment impairments associated with the Drosophila classic ga-
lactosemia model. Recently, Daenzer and co-workers reported
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that the Drosophilamodel did not show phenotypic rescue by
knocking out the GALK1 gene (Daenzer et al. 2016).
Additionally, double GALT and GALE mutants as well as
GALT and UGP mutants displayed severe abnormalities in
the coordinated locomotor movement, in NMJ formation, in
the synaptomatrix glycosylation and in the Wnt trans-synaptic
signaling (Jumbo-Lucioni et al. 2016).
These animal models are able to recapitulate many patho-
physiological aspects of classic galactosemia and expand the
molecular insights from bacterial and yeast models, bringing
new important insights of the underlying pathogenesis.
Therapeutic approaches in classic galactosemia
In 1935, Mason and Turner described how removing galac-
tose from the diet eliminated the neonatal toxicity and there-
after, dietary galactose restriction became the first recom-
mended therapy for galactosemia that still prevails nowadays.
Considering that classic galactosemia is characterized by
deficiency in UDP-hexoses, the potential therapeutic role of
uridine was evaluated in a 5-year longitudinal study of galac-
tosemic patients (Manis et al. 1997). Despite no improve-
ments in cognitive function, it remains to be clarified whether
uridine was able to enter the cells (Tang et al. 2012).
Aldose reductase inhibition has also been suggested as a
therapeutic option, since galactitol is an important pathogenic
agent. However, the fact that patients with GALK1 deficiency
experience galactitol accumulation but not the broad range of
severe long-term complications of classic galactosemia
strongly suggests a limited efficacy of aldose reductase inhib-
itors (Berry 1995).
Another ongoing therapeutic strategy under study concerns
the conversion of classic galactosemia into GALK1 deficien-
cy, a milder form of galactosemia in which patients do not
accumulate Gal-1-P. GALK1-deficient patients may present
cataracts (attributed to galactitol accumulation) and neurolog-
ical sequelae. In a review from the literature, Bosch et al.
reported a frequency of mental retardation in 7% of patients
(three out of 43) (Bosch et al. 2003). In a more recent study,
approximately 30% of patients (five out of 16) were described
as presenting mental retardation, which the authors could not
unambiguously attribute to GALK1 deficiency and hypothe-
sized that secondary factors could also take a toll (consanguin-
ity was excluded as a causative agent) (Hennermann et al.
2011). Using recombinant human GALK1 protein, a quanti-
tative high-throughput screening identified a number of small-
molecule GALK1 inhibitors, of which the spiro-benzoxazole
containing series emerged as lead compounds. These com-
pounds have been further optimized and validated in primary
patient fibroblasts, exhibiting reasonable pharmacokinetic
properties (Liu et al. 2015; Odejinmi et al. 2011; Tang et al.
2010; Wierenga et al. 2008).
Increased oxidative stress has been reported in the fruit fly
model of classic galactosemia, and superoxide dismutase-
mimicking manganese-based compounds proved beneficial
to GALT-null larvae and adult flies (Jumbo-Lucioni et al.
2014b). Moreover, it has been hypothesized that acetylated
anthocyanins derived from purple sweet potato color, previ-
ously shown to have a protective effect against galactose tox-
icity in mice on a high galactose diet (Lu et al. 2010; Zhang
et al. 2010), may alleviate galactosemia’s oxidative damage
(Timson 2014).
Until recently, the effect of a mutation was assumed to affect
only its coding potential. In recent years, however, there has been
increasing evidence that both exonic and deep intronic mutations
may affect splicing. Mutational analysis of Portuguese patients
revealed an intronic variation, c.820 + 13A>G (IVS8 + 13A>G),
as the second most frequent mutation. Functional characteriza-
tion of c.820 + 13A>G revealed it activates the cryptic donor site
c.820 + 14_820 + 15, leading to the exonization of the first 13
nucleotides of intron 8, thereby confirming that this intronic var-
iation is actually a disease-causing mutation. Coelho and co-
workers employed two locked nucleic acid (LNA) oligonucleo-
tides and themini-gene approach to successfully restore the splic-
ing profile, thus establishing a proof of concept for the applica-
tion of antisense therapy for mis-splicing mutations in classic
galactosemia (Coelho et al. 2015b).
Classic galactosemia: where do we stand?
After more than 100 years since the first description of galac-
tosemia, there are still many Bclouds gathering over
galactosemia^ (Anonymous 1982):
& The only currently available treatment, though very effec-
tive at preventing or resolving acute and potentially lethal
sequelae in the neonatal period, is ineffective in
preventing long-term sequelae. Despite early diagnosis
and early implementation of therapy, patients still go on
to develop burdensome chronic complications.
& Younger siblings of galactosemic patients put on a
galactose-restricted diet immediately after birth fail to
show a better clinical outcome than the older siblings later
in life.
& The reduction in galactose intake by restricting fruit and
vegetables seems to be negligible and it has been de-
scribed that a slightly higher galactose intake may actually
improve glycosylation abnormalities. Many countries
have now liberalized the therapy, currently advising a
lactose-free diet.
& Severe impairment of GALT activity results in the accu-
mulation of galactose metabolites and in UDP-hexoses
deficiency. As GALT substrate, Gal-1-P accumulation
has been widely pointed out as a key pathogenic agent.
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Glycosylation abnormalities are extensively reported in
classic galactosemia and have also been suggested as an
important pathogenic factor.
& Small-molecule GALK1 inhibitors that mitigate Gal-1-P
accumulation are being explored as possible therapeutic
agents for classic galactosemia and studies on patients’
fibroblasts have shown encouraging results.
& The pathogenic mechanism underlying the severe impair-
ment of GALTactivity is protein misfolding and/or aggre-
gation, leading to the recognition of classic galactosemia
as a conformational disorder. In recent years, the paradigm
that the great majority of inherited diseases are conforma-
tional disorders has emerged, which has provided a com-
mon framework for the analysis of rather diverse diseases,
including Alzheimer’s and Parkinson’s diseases, and
many other proteinopathies.
& The most suitable therapeutic strategy for conformational
disorders focuses on pharmacological/chemical chaper-
ones, which support the proper folding of protein variants
and improve their stability and consequently their activity
above a functional threshold. In the specific case of classic
galactosemia, a chaperone-based therapy would aim to
mitigate GALT misfolding and aggregation, thereby en-
hancing GALT activity/stability. Considering the molecu-
lar heterogeneity of theGALT locus, which leads to a high
number of protein variants, ideally pharmacological/
chemical chaperones should act in a non-mutation-
specific way.
& The recently reported crystallographic structure of human
GALT provides new insights on the mutations’ effect on
GALT structure and function, and will support the design
of compounds with pharmacological interest.
& The improvement of patients’ outcome is also hindered by
differences in care provided worldwide to galactosemic
patients (Jumbo-Lucioni et al. 2012).
& In 2012, an international network of galactosemia—
GalNet —was established, aiming at the harmonization
and improvement of patients’ outcome and care (Rubio-
Gozalbo et al. 2016). It includes professionals from centers
in 18 European countries, Israel, Australia, and the USA
(www.galactosemianetwork.org). Thus far, a patient
Registry has been developed and is currently being
implemented across countries; expert- and evidence-
based guidelines for treatment and follow-up have been
devised, and collaborative research is taking place.
In conclusion, although the outcome for classic galacto-
semia is still very disappointing at present, there have been
encouraging developments in recent years. With the recent
growth of knowledge on the molecular basis of galactosemia,
there is now a new hope for the development of a truly effec-
tive therapy, possibly combining different yet complementary
approaches.
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